



Board of Directors of 19 November 2025: medicines approved for reimbursement

Green light for a generic antiviral and two new indications of a monoclonal antibody

At its meeting on 19 November 2025, the AIFA Board of Directors approved reimbursement for two extensions of therapeutic indications for the monoclonal antibody dupilumab, and for a new generic of an antiviral drug.

Dupixent (dupilumab) will now be reimbursed for additional indications in the treatment of chronic obstructive pulmonary disease (COPD) and eosinophilic esophagitis, a chronic inflammatory condition of the esophagus.

The second medicine approved for reimbursement is the generic emtricitabine/rilpivirine/tenofovir alafenamide **Viatris**, a triple combination for the treatment of HIV-1 infection.